Novel oral anticoagulants: A new era in anti-thrombotic therapy

For over half-a-century vitamin K antagonists (VKAs) served our patients well as effective anticoagulants, several novel oral anticoagulants (NOACs) have emerged and are now available as a suitable alternative for stroke prevention, venous thromboembolism prevention and treatment and to reduce vascular events in acute coronary syndrome. Compared to VKAs, the novel agents have several advantages including an improved efficacy/safety ratio, a faster onset of action, shorter plasma half-life, few drug or food interactions, and no requirement for regular monitoring. Although very promising in many regards their proper use will require new approaches in many daily aspects with dose adjustments may be required for patients with severe renal impairment or in the setting of drug interactions. The lack of specific antidote makes reversing their effect during bleeding or for emergency surgery particularly a major challenge. This article provides a focused overview on their current status.

Object Details

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: Novel oral anticoagulants: A new era in anti-thrombotic therapy ; volume:05 ; number:05 ; year:2013 ; pages:247-253 ; Ibnosina journal of medicine and biomedical sciences ; 05, Heft 05 (2013), 247-253

Contributors, Places and Time

• Contributor: Shlebak, Abdul

Further information

• DOI: 10.4103/1947-489X.210553
• URN: urn:nbn:de:101:1-2022101002375289021365
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 15.08.2025, 7:31 AM CEST